ABSTRACT
Current recombinant human immunodeficiency virus (HIV) gp120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, "fusion-competent" HIV vaccine immunogens were generated that capture the transient envelope-CD4-coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E. Development of these fusion-dependent immunogens may lead to a broadly effective HIV vaccine.
Subject(s)
AIDS Vaccines/immunology , Gene Products, env/immunology , HIV Antibodies/immunology , HIV Antigens/immunology , HIV-1/immunology , Animals , CD4 Antigens/metabolism , Cell Fusion , Coculture Techniques , Epitopes/immunology , Gene Products, env/chemistry , Gene Products, env/metabolism , Giant Cells , HIV Antibodies/biosynthesis , HIV Antigens/chemistry , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/immunology , HIV Envelope Protein gp41/metabolism , HIV Infections/virology , HIV-1/isolation & purification , HIV-1/physiology , Humans , Mice , Mice, Transgenic , Neutralization Tests , Protein Conformation , Receptors, CCR5/metabolism , Tumor Cells, CulturedABSTRACT
The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.
Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/therapeutic use , HIV Infections/prevention & control , Organophosphonates , Organophosphorus Compounds/pharmacology , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/drug effects , Adenine/administration & dosage , Adenine/pharmacology , Animals , Antibodies, Viral/blood , Antiviral Agents/administration & dosage , Base Sequence , Cells, Cultured , HIV Infections/drug therapy , Humans , Injections, Subcutaneous , Leukocytes, Mononuclear/virology , Lymph Nodes/virology , Macaca fascicularis , Molecular Sequence Data , Organophosphorus Compounds/administration & dosage , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/isolation & purification , TenofovirABSTRACT
HIV vaccine development has been hampered by the inability of conventional immunogens to elicit antibodies capable of neutralizing primary isolates of the virus. Recent studies using 'fusion-competent' immunogens that capture transitional intermediate structures of the functioning envelope protein suggest that this goal may now be achievable.
Subject(s)
AIDS Vaccines/immunology , HIV Infections/prevention & control , HIV/immunology , Vaccines, Synthetic/immunology , Animals , HIV Envelope Protein gp120/immunology , Humans , Neutralization Tests , Peptide Fragments/immunologyABSTRACT
The effect of dosing frequency on zidovudine (ZDV) prophylaxis against simian immunodeficiency virus (SIV) infection was examined in long-tailed macaque monkeys (Macaca fascicularis). The results indicate that dosing frequency is extremely important for drug efficacy. The monkeys were divided into three groups based on dosing frequencies of 6-, 8-, or 12-h intervals. All were given a total daily dose of 100 mg/kg of ZDV. The drug was administered subcutaneously starting 24 h before SIV inoculation, and treatment continued for an additional 28 days. With the total daily dose held constant, ZDV was most therapeutic when administered at 12-h intervals, less effective at 8-h intervals, and least effective at 6-h intervals. These results indicate that early ZDV treatment based on infrequent but high dosages may increase the antiretroviral effect of the drug. These findings could serve as a model for ZDV chemoprophylaxis in humans. In cases involving accidental exposure to SIV or human immunodeficiency virus (HIV-1 or HIV-2), immediate, high-dosage therapies may be most therapeutic.
Subject(s)
Macaca fascicularis , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus , Zidovudine/therapeutic use , Anemia/chemically induced , Animals , Antibodies, Viral/blood , Base Sequence , DNA Primers/chemistry , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Leukocytes, Mononuclear/microbiology , Lymph Nodes/microbiology , Lymphocyte Subsets/immunology , Male , Molecular Sequence Data , Polymerase Chain Reaction , Simian Acquired Immunodeficiency Syndrome/microbiology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Immunodeficiency Virus/growth & development , Simian Immunodeficiency Virus/immunology , Time Factors , Viremia/drug therapy , Viremia/microbiology , Zidovudine/administration & dosage , Zidovudine/toxicityABSTRACT
The simian acquired immunodeficiency syndrome (SAIDS) in macaques at the Washington Regional Primate Research Center is associated with a type D retrovirus known as SAIDS-D/WA. We tested the ability of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA) to inhibit the in vitro cytopathic effect (syncytium formation) and infectivity of the SAIDS-D/WA virus. Raji cell cultures were infected with virus and treated with various concentrations of AZT, ddC, and ddA. The ability of these drugs to inhibit replication of the SAIDS-D/WA virus in Raji cells was monitored by syncytium formation, expression of viral antigen, and reverse transcriptase assay. At concentrations of 4, 40, and 400 microM, AZT completely blocked the viral infectivity and inhibited the cytopathic effect of SAIDS-D/WA. Likewise, ddC was inhibitory at concentrations of 5 and 50 microM and ddA was inhibitory at 100 and 200 microM. AZT, ddC, and ddA became cytostatic to Raji cells with increasing drug concentrations. AZT also partially inhibited SAIDS-D/WA replication in previously infected Raji cell cultures, and viral inhibition increased in response to the concentration of AZT. These data indicate that AZT, ddC, and ddA are effective antiretroviral agents that merit further evaluation, including clinical trials, in animal models with AIDS-like diseases.
Subject(s)
Antiviral Agents , Simian Immunodeficiency Virus/drug effects , Animals , Cell Line , Cytopathogenic Effect, Viral/drug effects , Dideoxyadenosine , Dideoxynucleosides/pharmacology , Humans , Macaca mulatta , Microbial Sensitivity Tests , Reverse Transcriptase Inhibitors , Simian Immunodeficiency Virus/enzymology , Zalcitabine , Zidovudine/pharmacologyABSTRACT
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA) acts as a reverse transcriptase inhibitor of retroviruses and has been shown to be effective against acute simian immunodeficiency virus (SIV) infection in macaques. To study its efficacy at different stages of infection, we tested PMPA in cynomolgus macaques (Macaca fascicularis) that had been chronically infected with SIVMne for at least 19 weeks before treatment was begun. PMPA was administered subcutaneously in a single daily dose of either 30 or 75 mg/kg body weight for 28 days. Within < or = 2 weeks of treatment, PMPA in both dosing regimens reduced SIV levels by >99% in the plasma or peripheral blood mononuclear cells; in some macaques SIV levels were reduced to below the lower quantitation limit. At a dose of 30 mg/kg/day PMPA was well tolerated, causing no side effects while increasing the mean CD4+ cell counts in animals that received this dose. Thus PMPA seems to be a promising agent for use against retroviral infections.
Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/therapeutic use , Macaca fascicularis/virology , Organophosphonates , Organophosphorus Compounds/therapeutic use , Retroviridae Infections/drug therapy , Simian Immunodeficiency Virus/drug effects , Adenine/therapeutic use , Adenine/toxicity , Animals , Antiviral Agents/pharmacokinetics , CD4-Positive T-Lymphocytes/drug effects , Drug Evaluation , Lymphocyte Count/drug effects , Lymphocyte Subsets/cytology , Lymphoid Tissue/pathology , Lymphoid Tissue/virology , Organophosphorus Compounds/toxicity , Retroviridae Infections/blood , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/growth & development , TenofovirABSTRACT
Simian immunodeficiency virus (SIV), which causes an acquired immunodeficiency syndrome in macaques, is a lentivirus that is morphologically, antigenically, genetically, and biologically similar to the human immunodeficiency virus (HIV). Because of these similarities, the SIV model represents a unique opportunity for in vitro and in vivo testing of antiretroviral agents. Since antiretroviral agents may exhibit different properties in different cells in vitro, more than one cell line may be necessary to evaluate the efficacy and modes of action of an antiretroviral agent. Initially we tested ten cell lines for their permissiveness to five SIV isolates. One B-cell line (AA-2) and one T-cell line (HuT 78) were selected to test antiretroviral agents since both were extremely permissive for SIVmac251, an isolate with a high rate of infectivity. Using this optimized in vitro testing protocol, we screened ten antiretroviral agents for their ability to inhibit SIV replication. Six of the compounds completely inhibited SIV viral antigen expression. Based on the selectivity index, 3'-azido-3'-dideoxythymidine, 3'-azido-2',3'-dideoxyuridine, and 3'-fluoro-3'-deoxythymidine appear to be the most efficacious antiretroviral agents against SIVmac251. Several different assays for determining viral antigen inhibition were conducted and the results of these assays were comparable. Our results demonstrate that the SIV in vitro model is a valuable screening tool for determining the efficacy and toxicity of new antiretroviral agents.
Subject(s)
Antiviral Agents/pharmacology , Microbial Sensitivity Tests/methods , Simian Immunodeficiency Virus/drug effects , Animals , Antigens, Viral/biosynthesis , Cell Line , Drug Evaluation, Preclinical/methods , Electrophoresis, Polyacrylamide Gel , Fluorescent Antibody Technique , Humans , Macaca nemestrina , RNA-Directed DNA Polymerase/metabolism , Simian Immunodeficiency Virus/enzymology , Simian Immunodeficiency Virus/pathogenicity , Virus Replication/drug effectsABSTRACT
A rapid, sensitive and specific antigen capture (AC) assay has been established for the detection of p27 core protein of SAIDS type-D retrovirus (SRV). SRV p27 antigen in test samples was identified on rabbit anti-p27 IgG-coated microtiter plates by the addition of biotinylated rabbit anti-p27 IgG. This assay was specific for the p27 core protein of SRV-1 and SRV-2 and provided semi-quantitative results in less than 7 hours. Results of the AC assay were highly correlated with those of reverse transcriptase (RT), immunofluorescence and immunoblotting assays. However, the AC assay was faster and more sensitive than the other three assays. The AC assay also provided a rapid diagnostic tool for the detection of SRV in plasma, serum and peripheral blood lymphocyte cocultures. In addition to mass screening of SRV infection in macaque colonies, the AC assay also will be valuable for monitoring the efficacy of antiretroviral agents against SRV in vitro and in vivo.
Subject(s)
Antigens, Viral/analysis , Macaca nemestrina/microbiology , Macaca/microbiology , Monkey Diseases/diagnosis , Retroviridae Infections/veterinary , Simian Immunodeficiency Virus/immunology , Animals , Antigens, Viral/blood , Cell Line , Electrophoresis, Polyacrylamide Gel , Epitopes , Fluorescent Antibody Technique , Immunoblotting , Macaca mulatta/microbiology , Retroviridae Infections/diagnosis , Simian Immunodeficiency Virus/isolation & purificationABSTRACT
Four dosing regimens of 2',3'-dideoxycytidine (ddC) were administered intravenously for 10 to 28 days to 18 pigtailed macaques with simian acquired immunodeficiency syndrome. Ten macaques naturally infected with simian acquired immunodeficiency syndrome retrovirus serotype 2 (SRV-2), the etiologic agent of simian acquired immunodeficiency syndrome, received ddC by continuous intravenous infusion or by a daily bolus injection for 10 to 12 days. Another eight macaques that were negative for SRV-2 and antibody received ddC prophylaxis prior to challenge with virus and continued to receive ddC therapy for up to 28 days postchallenge. All monkeys treated with a continuous intravenous dose of ddC, which maintained plasma concentrations of ddC at levels known to inhibit SRV-2 in vitro, developed dose-related toxic effects, including leukopenia, anemia, lethargy, and decreased appetite. Monkeys treated with a daily bolus injection of ddC experienced more severe toxic effects than those on the continuous intravenous regimen, including exfoliative dermatitis and peripheral neuropathy. At the concentrations of ddC administered, no significant inhibition of SRV-2 replication was detected in naturally infected macaques. However, a prophylactic regimen of ddC did have an inhibitory effect on SRV-2. Our findings suggest that ddC may be valuable as a short-term prophylactic treatment rather than as a long-term therapy.
Subject(s)
Retroviridae Infections/drug therapy , Retroviruses, Simian/drug effects , Zalcitabine/therapeutic use , Animals , Antigens, Viral/analysis , Fluorescent Antibody Technique , Macaca nemestrina , Retroviridae Infections/pathology , Retroviruses, Simian/immunology , Zalcitabine/toxicityABSTRACT
Long-tailed macaques chronically infected with simian immunodeficiency virus (SIV) were treated for 4 or 8 weeks with daily subcutaneous doses of the antiretroviral compound 9-(2-phosphonylmethoxyethyl)adenine (PMEA). The efficacy of PMEA was evaluated by monitoring cell-free virus in plasma, virus titer and viral DNA in peripheral blood mononuclear cells, and absolute numbers of lymphocyte subsets. In mock-treated control macaques, virus titers changed minimally. However, in treated macaques, PMEA exhibited impressive effects, leading to the disappearance of virus in the blood within the first week of treatment and lasting through the fourth week of treatment. The results indicate that PMEA can effectively reduce SIV in chronically infected macaques and offer an optimistic perspective for therapeutic intervention against human immunodeficiency virus infection.
Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/therapeutic use , Organophosphonates , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus/isolation & purification , Adenine/administration & dosage , Adenine/pharmacology , Adenine/therapeutic use , Adenine/toxicity , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Antiviral Agents/toxicity , Chronic Disease , DNA, Viral/analysis , DNA, Viral/blood , Leukocytes, Mononuclear/virology , Lymphocyte Subsets , Macaca fascicularis , Proviruses , RNA-Directed DNA Polymerase , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/virologyABSTRACT
The differential use of CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) may be intimately involved in the transmission and progression of human immunodeficiency virus infection. Changes in coreceptor utilization have also been noted upon adaptation of primary isolates (PI) to growth in established T-cell lines. All of the T-cell line-adapted (TCLA) viruses studied to date utilize CXCR4 but not CCR5. This observation had been suggested as an explanation for the sensitivity of TCLA, but not PI, viruses to neutralization by recombinant gp120 antisera and V3-directed monoclonal antibodies, but recent studies have shown coreceptor utilization to be independent of neutralization sensitivity. Here we describe a newly isolated TCLA virus that is sensitive to neutralization but continues to utilize both CXCR4 and CCR5 for infection. This finding further divorces coreceptor specificity from neutralization sensitivity and from certain changes in cell tropism. That the TCLA virus can continue to utilize CCR5 despite the changes that occur upon adaptation and in the apparent absence of CCR5 expression in the FDA/H9 T-cell line suggests that the interaction between envelope protein and coreceptor may be mediated by multiple weak interactions along a diffuse surface.
Subject(s)
HIV-1/metabolism , Receptors, CCR5/metabolism , T-Lymphocytes/virology , Adaptation, Biological , Base Sequence , DNA, Viral , HIV Envelope Protein gp120/genetics , HIV-1/genetics , HIV-1/immunology , Humans , Molecular Sequence Data , Neutralization Tests , Sequence Analysis, DNA , Tumor Cells, CulturedABSTRACT
Pregnant macaques were used as a natural model for maternal-infant transmission of SRV-2 retrovirus. Fifty-one pregnant females were placed into one of four virus/antibody groups. Nonviremic mothers produced 100% virus-negative offspring at birth. In contrast, viremic mothers produced offspring which were 17% virus-negative and 83% virus-positive at birth. SRV-2 infection occurred principally in utero by the transplacental route. Infants born to viremic mothers exhibited low birth weight, prematurity, high perinatal death, and increased incidence of SAIDS.
Subject(s)
Maternal-Fetal Exchange , Retroviruses, Simian , Simian Acquired Immunodeficiency Syndrome/transmission , Animals , Animals, Newborn , Antibodies, Viral/blood , Birth Weight , Female , Macaca nemestrina , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/microbiology , Retroviruses, Simian/immunology , Retroviruses, Simian/isolation & purification , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/microbiology , Survival Rate , ViremiaABSTRACT
The 50% macaque infectious dose (MID50) and pathogenesis of uncloned simian immunodeficiency virus (isolated from a pigtailed macaque, SIVmne) was determined in longtailed macaques (Macaca fascicularis). Five pairs of macaques were inoculated with 10-fold dilutions of the virus stock, and one macaque was mock-infected. The virologic and clinical status of these macaques was monitored for up to 80 weeks. The MID50 of SIVmne was determined to be 10(2) cell culture infectious dose of the original virus stock. In order to test the infectivity and pathogenesis of an established viral dose, six additional macaques were inoculated with 10x MID50 (10(3) cell culture infectious dose) of the SIVmne. The virologic and clinical status of these macaques was monitored for 40 weeks. All of the macaques inoculated with 10x MID50 or greater became infected as evidenced by seroconversion and consistent virus isolation from peripheral blood mononuclear cells. Macaques infected with SIVmne had an initial sharp decrease in CD2, CD20, CD4, CD8, and CD4CD29 lymphocyte subsets, whereas the CD4:CD8 ratio increased. Viremic macaques developed persistent slight to moderate peripheral lymphadenopathy approximately 3 to 4 weeks after inoculation. Four macaques subsequently died of AIDS-like disease at 29, 33, 42, and 80 weeks after inoculation. Data obtained from the viral titration study and the acute infection model will aid in the development of animal trials to evaluate antiretroviral therapies and preventive vaccines against human immunodeficiency virus infection.
Subject(s)
Macaca fascicularis/microbiology , Simian Acquired Immunodeficiency Syndrome/transmission , Simian Immunodeficiency Virus/pathogenicity , Animals , CD4-CD8 Ratio , Lymphocyte Subsets/pathology , Simian Acquired Immunodeficiency Syndrome/complications , Simian Acquired Immunodeficiency Syndrome/pathologyABSTRACT
The antiretroviral drugs azidothymidine (AZT) and 9-(-2-phosphonyl-methoxyethyl)adenine (PMEA) were individually tested for prevention of simian immunodeficiency virus (SIVmne) infection in macaques (Macaca fascicularis). Macaques were pretreated with either drug before inoculation with SIVmne, and drug treatment was continued for four weeks. The virus, antibody, and clinical status of the macaques was monitored for up to 36 weeks following inoculation. While AZT prophylaxis resulted in reduced virus load in some macaques, PMEA prophylaxis was highly efficacious in preventing acute SIVmne infection.
Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/therapeutic use , Organophosphonates , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/immunology , Zidovudine/therapeutic use , Adenine/therapeutic use , Animals , DNA, Viral/analysis , Lymphocyte Subsets/immunology , Macaca mulatta , Polymerase Chain Reaction , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Acquired Immunodeficiency Syndrome/physiopathology , Simian Immunodeficiency Virus/isolation & purification , Splenomegaly , Time FactorsABSTRACT
The relative resistance of human immunodeficiency virus type 1 (HIV-1) primary isolates (PIs) to neutralization by a wide range of antibodies remains a theoretical and practical barrier to the development of an effective HIV vaccine. One model to account for the differential neutralization sensitivity between Pls and laboratory (or T-cell line-adapted [TCLA]) strains of HIV suggests that the envelope protein (Env) complex is made more accessible to antibody binding as a consequence of adaptation to growth in established cell lines. Here, we revisit this question using genetically related PI and TCLA viruses and molecularly cloned env genes. By using complementary techniques of flow cytometry and virion binding assays, we show that monoclonal antibodies targeting the V3 loop, CD4-binding site, CD4-induced determinant of gp120, or the ectodomain of gp41 bind equally well to PI and TCLA Env complexes, despite large differences in neutralization outcome. The data suggest that the differential neutralization sensitivity of PI and TCLA viruses may derive not from differences in the initial antibody binding event but rather from differences in the subsequent functioning of the PI and TCLA Envs during virus entry. An understanding of these as yet undefined differences may enhance our ability to generate broadly neutralizing HIV vaccine immunogens.
Subject(s)
Antibodies, Monoclonal/immunology , HIV Antibodies/immunology , HIV Infections/virology , HIV-1/immunology , Antibody Affinity , Cell Line , Flow Cytometry , Gene Products, env/immunology , HIV Infections/immunology , HIV-1/metabolism , HIV-1/pathogenicity , Humans , Neutralization Tests , T-Lymphocytes/virology , Transfection , Virion/immunology , Virion/pathogenicityABSTRACT
Monoclonal antibodies (MoAbs) to the major gag core protein p27 and a viral protein p44 of type D retrovirus (SRV-2) were produced and used in the detection of SRV-2 antigens in infected Raji cells and in tissues from macaques with simian acquired immunodeficiency syndrome (SAIDS) and retroperitoneal fibromatosis (RF). Anti-p44 MoAb showed inhibition of syncytium formation by both SRV-1- and SRV-2-infected Raji cells.
Subject(s)
Antibodies, Monoclonal/biosynthesis , Antigens, Viral/analysis , Retroviruses, Simian/immunology , Animals , Antibodies, Monoclonal/immunology , Antigens, Viral/immunology , Blotting, Western , Cell Line , Flow Cytometry , Fluorescent Antibody Technique , Gene Products, gag , Hybridomas , Immunohistochemistry , Neutralization Tests , Retroviridae Proteins/immunologyABSTRACT
We report that simian immunodeficiency virus (SIV) infection in macaques is a valuable animal model for studying post-exposure chemoprophylaxis (PECP). PECP with the acyclic nucleoside reverse transcriptase inhibitors 9-(2-phosphonylmetho-xyethyl)adenine (PMEA) and (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) at early viral infection can provide long-term protection against subsequent heterologous SIV challenge. Eight macaques previously treated with PECP (called PECP macaques) and four naive controls were challenged intravenously with the most virulent form of SIV, SIV(PBj14). All controls showed signs of SIV(PBj14)-induced acute disease syndrome on days 6 and 7 post-inoculation (PI). One had a fatal viral infection and two surviving controls had persistent infection and decreased CD4+ cell count. Virologic studies of the three surviving controls revealed SIV in multiple lymphoid tissues and peripheral blood mononuclear cells (PBMCs) at necropsy. In contrast, the PECP macaques showed none to mild signs of acute disease syndrome at day 9 PI and exhibited only transient SIV infection in PBMCs between weeks 1 and 8 PI. In virologic studies of five PECP macaques necropsied, two macaques were SIV-negative and the other three were SIV-positive only in either lymph node or bone marrow. Three SIV(PBj14)-challenged PECP macaques, that were randomly reserved for a follow-up study for > 4.0 years PI showed extremely low to undetectable levels of PBMC-associated viremia and normal to increased levels of CD4 + and CD8 + cell counts throughout the study. Our results indicate that early PECP could activate immune responses to protect against subsequent infection with heterologous challenge virus.
Subject(s)
Adenine/analogs & derivatives , Organophosphonates , Organophosphorus Compounds/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/isolation & purification , Adenine/therapeutic use , Animals , DNA, Viral/analysis , Disease Models, Animal , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Infectious Disease Transmission, Vertical/prevention & control , Macaca fascicularis , Polymerase Chain Reaction , Simian Acquired Immunodeficiency Syndrome/transmission , TenofovirABSTRACT
A reverse transcriptase inhibitor, 9-(2-phosphonylmethoxyethyl)adenine (PMEA), was evaluated for efficacy against acute simian immunodeficiency virus (SIV) infection in juvenile macaques (Macaca fascicularis). Macaques were pretreated subcutaneously with PMEA for 48 h before SIV inoculation. Drug treatment continued for an additional 28 days. Efficacy of PMEA was determined by detection of SIV in blood, SIV DNA in peripheral blood mononuclear cells, and SIV antibodies. Protection from acute SIV infection occurred in 83% of macaques treated with 20 mg/kg/day versus 50% of macaques treated with 10 mg/kg/day. Several PMEA-treated macaques developed mild dermatitis that disappeared when the 4-week therapy ended. The results of these experiments indicate that preexposure prophylaxis with PMEA can prevent acute SIV infection in macaques. Since PMEA demonstrates profound inhibition of retrovirus infection, it may have utility as a chemoprophylactic agent for humans exposed to SIV or human immunodeficiency virus.
Subject(s)
Adenine/analogs & derivatives , Organophosphonates , Simian Acquired Immunodeficiency Syndrome/prevention & control , Adenine/therapeutic use , Animals , Antibodies, Viral/biosynthesis , Base Sequence , DNA Primers/chemistry , DNA, Viral/analysis , Dose-Response Relationship, Drug , Leukocytes, Mononuclear/microbiology , Macaca , Molecular Sequence Data , Simian Immunodeficiency Virus/immunology , T-Lymphocyte Subsets/immunologyABSTRACT
We have examined the relationship between coreceptor utilization and sensitivity to neutralization in a primary isolate of human immunodeficiency virus type 1 and its T-cell line-adapted (TCLA) derivative. We determined that adaptation of the primary-isolate (PI) virus 168P results in the loss of the unique capacity of PI viruses to utilize the CCR5 coreceptor and in the acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs). In experiments wherein infection by 168P is directed via either the CCR5 or the CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions bearing a molecularly cloned 168P envelope protein, remains refractory to neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor utilized. This study suggests that coreceptor utilization is not a primary determinant of differential neutralization sensitivity in PI and TCLA viruses.
Subject(s)
Antibodies, Monoclonal/immunology , HIV Antigens/immunology , HIV Envelope Protein gp120/immunology , HIV-1/immunology , HIV-1/metabolism , Peptide Fragments/immunology , Receptors, CCR5/metabolism , Receptors, CXCR4/metabolism , Animals , Base Sequence , COS Cells , Cell Line , Cloning, Molecular , DNA, Viral , Genes, env , HIV Antibodies/immunology , HIV-1/genetics , HIV-1/isolation & purification , Humans , Molecular Sequence Data , Neutralization TestsABSTRACT
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA), an acyclic nucleoside phosphonate analog, is one of a new class of potent antiretroviral agents. Previously, we showed that PMPA treatment for 28 days prevented establishment of persistent simian immunodeficiency virus (SIV) infection in macaques even when therapy was initiated 24 h after intravenous virus inoculation. In the present study, we tested regimens involving different intervals between intravenous inoculation with SIV and initiation of PMPA treatment, as well as different durations of treatment, for the ability to prevent establishment of persistent infection. Twenty-four cynomolgus macaques (Macaca fascicularis) were studied for 46 weeks after inoculation with SIV. All mock-treated control macaques showed evidence of productive infection within 2 weeks postinoculation (p.i.). All macaques that were treated with PMPA for 28 days beginning 24 h p.i. showed no evidence of viral replication following discontinuation of PMPA treatment. However, extending the time to initiation of treatment from 24 to 48 or 72 h p.i. or decreasing the duration of treatment reduced effectiveness in preventing establishment of persistent infection. Only half of the macaques treated for 10 days, and none of those treated for 3 days, were completely protected when treatment was initiated at 24 h. Despite the reduced efficacy of delayed and shortened treatment, all PMPA-treated macaques that were not protected showed delays in the onset of cell-associated and plasma viremia and antibody responses compared with mock controls. These results clearly show that both the time between virus exposure and initiation of PMPA treatment as well as the duration of treatment are crucial factors for prevention of acute SIV infection in the macaque model.